ABOVE: © ISTOCK.COM, MICHAEL VI
Update (April 26): On April 23, officials at the US Centers for Disease Control and Prevention and the Food and Drug Administration lifted the pause on the Johnson & Johnson vaccine. The FDA will add a warning about the risk for developing rare blood clots to fact sheets given to providers and patients, Reuters reports.
Following six cases of rare blood clots in women who had received Johnson & Johnson’s COVID-19 vaccine in the US, the Food and Drug Administration and the Centers for Disease Control and Prevention have recommended a temporary suspension of its rollout. In a statement released today (April 13), the agencies announced that they are investigating the reports of cerebral venous sinus thrombosis (CVST), the same condition observed as an extremely rare side effect of AstraZeneca’s COVID-19 vaccine.
“Until that process is complete, we are recommending a pause in the use ...
